Reneo Pharmaceuticals Statistics
Share Statistics
Reneo Pharmaceuticals has 3.34M
shares outstanding. The number of shares has increased by -90%
in one year.
| Shares Outstanding | 3.34M |
| Shares Change (YoY) | -90% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 81.62% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,413 |
| FTD / Avg. Volume | 7.86% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.63 and the forward
PE ratio is null.
Reneo Pharmaceuticals's PEG ratio is
0.
| PE Ratio | -0.63 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.55 |
| P/FCF Ratio | -0.77 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Reneo Pharmaceuticals has an Enterprise Value (EV) of 22.41M.
| EV / Sales | 0 |
| EV / EBITDA | -0.27 |
| EV / EBIT | -0.35 |
| EV / FCF | -0.35 |
Financial Position
The company has a current ratio of 5.87,
with a Debt / Equity ratio of 0.
| Current Ratio | 5.87 |
| Quick Ratio | 5.87 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -87.34% and Return on Invested Capital is -94.16%.
| Return on Equity | -87.34% |
| Return on Assets | -72.03% |
| Return on Invested Capital | -94.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-9,673,500 |
| Employee Count | 8 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 650K |
| Effective Tax Rate | -0.84% |
Stock Price Statistics
The stock price has increased by 8.33% in the
last 52 weeks. The beta is 0.22, so Reneo Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.22 |
| 52-Week Price Change | 8.33% |
| 50-Day Moving Average | 14.93 |
| 200-Day Moving Average | 16.04 |
| Relative Strength Index (RSI) | 69.89 |
| Average Volume (20 Days) | 17,983 |
Income Statement
| Revenue | n/a |
| Gross Profit | -525K |
| Operating Income | -83.05M |
| Net Income | -77.39M |
| EBITDA | -82.23M |
| EBIT | -82.4M |
| Earnings Per Share (EPS) | -25.23 |
Full Income StatementBalance Sheet
The company has 27.63M in cash and 973K in
debt, giving a net cash position of 26.66M.
| Cash & Cash Equivalents | 27.63M |
| Total Debt | 973K |
| Net Cash | 26.66M |
| Retained Earnings | -218.47M |
| Total Assets | 78.72M |
| Working Capital | 76.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -63.68M
and capital expenditures -221K, giving a free cash flow of -63.9M.
| Operating Cash Flow | -63.68M |
| Capital Expenditures | -221K |
| Free Cash Flow | -63.9M |
| FCF Per Share | -20.84 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
